Ir para o conteúdo principal

Bio-Techne (NASDAQ: TECH) — Perfil da empresa, notícias e dados financeiros

Logo de Bio-Techne
TECH Bio-Techne
Bio-Techne  primary media
Perfil da empresa

Bio-Techne

Bio-Techne is a life sciences company that develops, manufactures, and sells biological reagents, instrument systems, and clinical diagnostic products for the research and clinical diagnostic markets. Its offerings include recombinant proteins, antibodies, immunoassays, spatial biology tools, enzymes, cell culture media, microfluidic instruments, and molecular diagnostic controls. The company serves biotechnology firms, pharmaceutical companies, academic research institutions, and clinical laboratories globally. Bio-Techne operates through dedicated brands including R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, supporting applications in drug discovery, biomarker detection, cell therapy, and translational medicine.

Resumo

Public USParticipação acionária
1976Ano de fundação
1,001–5,000Funcionários
Minneapolis, United StatesSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Bio-Techne

  • Recombinant Proteins and Antibodies: Production and distribution of bioactive proteins, monoclonal and polyclonal antibodies, enzymes, and small molecules for life science research, cell culture, targeted protein degradation, and cell and gene therapy manufacturing.
  • Immunoassays and ELISA Solutions: Development of enzyme-linked immunosorbent assay kits, Simple Plex automated immunoassays, Luminex multiplex assays, and antibody arrays utilized in academic and pharmaceutical laboratories for precise biomarker quantification and disease research.
  • Automated Protein Analysis Systems: Provision of analytical instrument platforms including Simple Western, Maurice, Ella, and micro-flow imaging systems, enabling automated capillary electrophoresis, immunoassay execution, and microparticle analysis for biotherapeutic development and quality control.
  • Spatial Biology Platforms and Assays: Supply of RNAscope in situ hybridization probes, COMET spatial biology instrumentation, and tissue-based assay panels designed for targeted RNA and multiplexed protein detection across oncology and neuroscience research applications.
  • Clinical Diagnostic Quality Controls: Manufacturing of blood gas, hematology, CO-oximetry, and molecular diagnostic controls, along with contract development and manufacturing services provided to diagnostic equipment manufacturers and clinical testing laboratories.
  • Molecular Diagnostic Testing Kits: Provision of specialized molecular diagnostic assay kits, including Amplidex genetic testing and Quantidex oncology testing panels, designed for clinical laboratories evaluating genetic mutations and cancer biomarkers.

equipe executiva do Bio-Techne

  • Kim KeldermanCEO, President & Director
  • James T. HippelExecutive VP of Finance & CFO
  • Shane V. BohnenSenior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer
  • William A. GeistPresident of Protein Sciences Segment
  • Gary J. LathamVP & CTO
  • David ClairVice President of Investor Relations
  • Martin WirtzSenior Vice President of Strategy & Corporate Development
  • Cheryl BethuneSenior VP & Chief Human Resources Officer
  • Luca CicchettiManaging Director
  • Steven C. CrousePresident of Diagnostics & Spatial Biology Segment

Comunicados recentes

O que a Bio-Techne (TECH) comunicou ao mercado, do mais recente para o mais antigo.

  1. 10-Q/A | BIO-TECHNE Corp

Histórico de dividendos

Dividendos por ação pagos pela Bio-Techne , por ano fiscal.

Dividendos por ação da Bio-Techne por ano fiscal
Ano fiscalIntermediárioFinalEspecialTotal
FY2027(até o momento)———$0.2400
FY2026———$0.3200
FY2025———$0.3200
FY2024———$0.3200
FY2023———$0.6400

Principais indicadores financeiros

Resultados divulgados pela Bio-Techne , em USD.

Cap. de mercado
11,4 bi
Receita (TTM)
1,2 bi
P/L
66.8
LPA (diluído, TTM)
1.1
Dividend yield
0.3%
Margem de lucro
14.0%
Receita e lucro anuais da Bio-Techne
Fim do ano fiscalReceitaResultado operacionalLucro líquido
1,2 bi251,9 mi181,9 mi
1,2 bi102,3 mi73,4 mi
1,2 bi206,7 mi168,1 mi
1,1 bi298,9 mi285,3 mi